Lixin Science Secures RMB 50 Million Series A Funding Led by Cenova Capital

PEDaily (ID: pedaily2012) reported on June 16,Corliber (abbreviated as: Corliber) announced the recent completion of a Series A financing round of RMB 50 million. This round of financing wasCenova CapitalExclusively invested, with Hangzhou Yitian Capital serving as the financial advisor.

This round of financing will be allocated to operational and development expenditures over the next two years, including clinical trials and FDA/CFDA registration expenses for its two current flagship products: absorbable interference screws and absorbable bone graft substitutes. Following this financing round, Corliber will expand its product pipeline to include a series of new products, such as absorbable dental bone graft substitutes and suspension plates, metal anchors, and fillable biodegradable medical aesthetics products.

Previously, the company secured investment from`Manulife Ventures`seed investment round,``Sunflower``Venture CapitalLed the angel round,Shenzhen Liumulou Venture Capitalled the Pre-A round investment.

Corliber was founded on December 13, 2016,Co-founded by overseas-educated PhDs from the National University of Singapore, medical device industry experts from Zhejiang University, and physicians,Dedicated to the development of novel biomedical materials and orthopedic implant medical devices.Currently certified as a National High-Tech Enterprise and a Shenzhen High-Tech Enterprise, the company employs two Shenzhen High-Level Peacock Talents.

The company has established long-term collaborative partnerships with numerous hospitals, including Shanghai Sixth People's Hospital, Shanghai Ninth People's Hospital, Shanghai East Hospital, Affiliated Guanghua Stomatological Hospital of Sun Yat-sen University, Shenzhen Nanshan Hospital, Xiangya Hospital, and Henglen Stomatological Hospital, as well as with numerous renowned domestic and international universities, including the National University of Singapore, Shanghai Jiao Tong University, Zhejiang University, Sichuan University, Donghua University, and Tongji University.

Corliber has successfully mastered composite medical raw material preparation technologies, including the preparation of high-purity lactide monomers and the synthesis of high-purity ultra-high molecular weight medical-grade polylactic acid (PLA). The company also holds material innovation patents that are leading in China, such as hydroxyapatite (HA) core-shell structure modification and nano-HA dispersed composite materials. The absorbable bone materials developed by Corliber feature high strength, excellent toughness, heat resistance, high moldability, and promotion of bone formation. They are absorbable and degradable, with a controllable degradation rate synchronized with the orthopedic recovery cycle, and they elicit no inflammatory response. In terms of both cost and performance, these materials outperform imported products from top-tier international brands. In the fields of biomedical new materials and orthopedic implant medical devices, Corliber has achieved a leading advantage characterized by independent raw material production, import substitution, and dual innovation in both products and technologies.

Regarding the success of this financing round,Sun Yang, Founder of Corliber“This round of financing represents the strongest validation from investors of Corliber’s years of dedicated R&D and accumulated technological expertise. Cenova Capital has established a highly comprehensive investment layout across the upstream and downstream sectors of the orthopedics and dentistry industries. We deeply admire their investment philosophy, market reputation, and professional capabilities, and feel a strong strategic alignment. Looking ahead, we will continue to uphold our pragmatic, diligent, and excellence-driven ethos to advance the R&D of new pipelines and products, including Corliber’s dental artificial bone, suspension plates, metal anchors, and fillable biodegradable medical aesthetic products. We will also expedite the regulatory certification process for Corliber’s artificial bone and absorbable interference screws, while actively expanding academic research partnerships and commercialized sales channels.”